Breaking News

Dragonfly Therapeutics Appoints Joseph Eid as President of Research & Development

Eid brings 20 years of deep immunotherapy clinical development experience including as team leader at Merck.

Author Image

By: Charlie Sternberg

Associate Editor

Joseph E. Eid, M.D., has joined Dragonfly Therapeutics as president of Research and Development.   Eid brings 20 years of deep immunotherapy clinical development experience including as team leader at Merck in the Pembrolizumab (anti-PD-1 antibody) first in human trial leading to registration of KEYTRUDA. He will be responsible for all aspects of clinical development and research at Dragonfly.   “We are delighted to welcome Joe to Dragonfly,” said Bill Haney, co-founder and CEO o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters